No open-market selling at Braveheart Bio, Inc. in the past year, which is unusual. Instead ten corporate insiders bought into about $159 million worth of BRVE.
The largest purchase came from Forbion Growth Opportunities Fund III Cooperatief U.A. (10% Owner), about $34.6 million. C-suite participation is part of the picture here.
Last full quarter: net buying by insiders. Insiders bought in 1 of the last 7 full quarters.
| Filed | Insider | Role | Type | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Aug 11, 2026 | Andreessen Marc L | 10% Owner | Buy | 1,100,000 | $18.00 | $19.8M | SEC |
| Aug 11, 2026 | Chimovits Erez | Director | Buy | 1,666,667 | $18.00 | $30.0M | SEC |
| Aug 11, 2026 | Chimovits Erez | Director | Buy | 273,333 | $18.00 | $4.9M | SEC |
| Aug 11, 2026 | OrbiMed Genesis GP LLC | Director | Buy | 1,666,667 | $18.00 | $30.0M | SEC |
| Aug 11, 2026 | OrbiMed Genesis GP LLC | Director | Buy | 273,333 | $18.00 | $4.9M | SEC |
| Aug 7, 2026 | Forbion Growth Opportunities Fund III Cooperatief U.A. | 10% Owner | Buy | 1,680,000 | $18.00 | $30.2M | SEC |
| Aug 7, 2026 | Forbion Growth Opportunities Fund III Cooperatief U.A. | 10% Owner | Buy | 1,920,000 | $18.00 | $34.6M | SEC |
| Aug 7, 2026 | Rickey James Paul | CFO | Buy | 27,777 | $18.00 | $500K | SEC |
| Aug 7, 2026 | Viehbacher Christopher | Director | Buy | 83,333 | $18.00 | $1.5M | SEC |
| Aug 7, 2026 | Malek David I | Director | Buy | 4,166 | $18.00 | $75K | SEC |
| Aug 7, 2026 | Anderson Michele A. | Executive Officer | Buy | 1,111 | $18.00 | $20K | SEC |
| Aug 7, 2026 | Murdoch Travis | CEO | Buy | 83,333 | $18.00 | $1.5M | SEC |
| Aug 7, 2026 | Lubner David Charles | Director | Buy | 55,555 | $18.00 | $1000K | SEC |
In the last 12 months Braveheart Bio, Inc. insiders made open-market purchases worth about $159 million and sales worth about $0. Data comes from SEC Form 4 filings, updated every 30 minutes on CapitalSnitch.
The most recent open-market insider trade in BRVE was filed on 2026-08-11.
No congressional trades in BRVE were reported in the past two years. The full list is free on CapitalSnitch.
Public-record data for research and education, not investment advice. Insider sales are often pre-planned (10b5-1). Congress data: Data derived from public disclosures filed under the Ethics in Government Act and the STOCK Act, republished free for public transparency and news reporting. Disclosures may lag the trade by 45 days or more and show amounts only as ranges. This data may not be used for credit rating, loan underwriting, solicitation of money (political, charitable or other), direct-mail or commercial targeting (5 U.S.C. 13107).